Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Sensorion SAS, retaining the price target of €4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Sensorion SAS’s recent developments and future prospects. The company has shown promising results in its Phase 1/2 Audiogene study for children with profound hearing loss, particularly in Cohort 2, where two out of three children demonstrated significant improvements. The Data Monitoring Committee’s recommendation to continue the study based on safety and procedural tolerance further supports the potential of Sensorion’s SENS-501 treatment.
Additionally, the upcoming release of 6-month data in the first quarter of 2026 is anticipated to be a critical driver for the stock, with expectations of positive outcomes that could attract interest from major pharmaceutical companies like Novartis. The encouraging data from Regeneron’s similar OTOF program also suggests a favorable environment for Sensorion’s approach, potentially leading to strategic discussions with the FDA regarding the future path of SENS-501. These factors combined indicate a strong potential for growth and strategic opportunities for Sensorion, justifying the Buy rating.